3-V Biosciences is a biopharmaceutical company focused on discovering and developing novel therapeutics that modulate key pathways for treatment of oncology and infectious disease.  3-V utilizes an integrated discovery approach that looks beyond typical infectious disease targets to solutions that exploit a virus’ dependency on host pathways. This approach is designed to generate antiviral treatments with broad-spectrum activity and a high barrier to resistance and programs with multiple potential indications from a single discovery.

3-V’s innovative platform identifies targets through an initial antiviral lens by uncovering pathways required for viral replication. Targeting these interactions leads to new classes of therapeutics with the additional potential for indications outside of infectious disease. 3-V’s lead program targeting fatty acid synthase (FASN) shows the promise of this approach with potential in both oncology and chronic Hepatitis C (HCV).

ONCOLOGY THERAPEUTICS

Host-pathogen interactions yield promising targets for tumors that rely on cellular mechanisms for growth and replication. 3-V’s platform has produced a series of targets with the dual potential as antiviral and oncology agents.

ANTIVIRAL THERAPEUTICS

High barrier to the development of resistance: viruses depend on a high mutation rate to develop resistance to direct-acting agents.  3-V’s approach of exploiting a virus’ reliance on the body significantly decreases the ability of viral mutations to create resistance.

Broad-spectrum activity: different viruses requiring the same host proteins or pathways for replication will likely succumb to the same drug.  A single agent that inhibits one of these critical pathways could target all circulating strains of a particular virus (e.g., influenza), including strains that are resistant to traditional antiviral agents.  The same drug could potentially be used to treat other diseases caused by different viruses that depend on that same pathway.

The 3-V approach is to harness rigorous, innovative science coupled with best practices honed through years of experience in drug discovery and development.